Michael Dell identifies the next frontier for enterprise AI as applying models to vast stores of private, unused data. The winning strategy involves taking standard models and retraining them on this proprietary data, creating a unique competitive advantage and organizational knowledge that cannot be easily copied.

Since LLMs are commodities, sustainable competitive advantage in AI comes from leveraging proprietary data and unique business processes that competitors cannot replicate. Companies must focus on building AI that understands their specific "secret sauce."

The next inflection point will come from clever data generation strategies optimized for AI models, not human analysis. This "black box data" approach—like pooled screening with sequencing readouts—is vastly more scalable and creates a powerful, proprietary moat for companies.

The company's core strategy is "data-first," believing the true long-term differentiator in AI drug discovery is generating unique, high-quality experimental data, not just innovating on model architecture, which they see as prone to commoditization when trained on public data.

As AI models become commoditized, the ultimate defensibility comes from exclusive access to a unique dataset. A startup with a slightly inferior model but a comprehensive, proprietary dataset (e.g., all legal records) will beat a superior, general-purpose model for specialized tasks, creating a powerful long-term advantage.

Regeneron's Genetics Center is a key competitive advantage, functioning as a discovery engine for new drug targets. By sequencing millions of patient genomes and linking them to health records, it allows Regeneron to identify novel genetic variants associated with diseases, feeding its antibody development pipeline with proprietary targets.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

The competitive advantage in pharma isn't the sophistication of an AI algorithm, which is often a commodity built on third-party models. The true differentiator is the quality, relevance, and end-to-end consistency of the proprietary data used to train and validate these models. Poor data invalidates even the best analytics.

If a company and its competitor both ask a generic LLM for strategy, they'll get the same answer, erasing any edge. The only way to generate unique, defensible strategies is by building evolving models trained on a company's own private data.